Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Phase I/II results support further development of Leuvectin

Oct. 8, 1999

NCI supports clinical development of StressGen's lead product

Oct. 7, 1999

York Medical to commence phase I/II trial of head and neck cancer therapy

Sep. 30, 1999

ImmunoGen exercises put option

Sep. 30, 1999

StressGen completes phase I trial of HspE7

Sep. 28, 1999

TriAb prolongs disease progression in breast cancer patients

Sep. 27, 1999

GM-CSF and MDX-H210 assessed in pilot trial in cancer patients

Sep. 24, 1999

FDA accepts IND for ImmunoGen's tumor-activated prodrug

Sep. 23, 1999

Kyowa Hakko begins clinical testing of MAb as melanoma Rx

Sep. 21, 1999

Genzyme Molecular Oncology reports preclinical results, collaboration for aaATIII

Sep. 21, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...